Santella P J, Tanrisever B, Berman E
J Int Med Res. 1978;6(6):441-51. doi: 10.1177/030006057800600604.
Céfadroxil, a new semisynthetic oral cephalosporin, is absorbed similarly by fasted and non-fasted subjects, produces sustained serum levels and is eliminated at a relatively slow rate. These pharmacokinetic properties permit less frequent and more convenient dosage scheduling than cephalexin and cephradine and consequently greater patient compliance. Cefadroxil was evaluated for safety in 1051 patients and for efficacy in 1030 patients. Overall it achieved a 91.8% rate of clinical success resulting from 881 complete cures and sixty-five clinical cures. Among 363 patients with respiratory tract infections and 471 patients with genito-urinary tract infections, cefadroxil treatment produced 97.5% and 84.5% clinical success, respectively. In the remaining infectious diseases treated, cefadroxil therapy resulted in 99.0% clinical success. Cefadroxil eradicated 87% of 1110 pathogens isolated, among which the most predominant pathogens were Staphylococcus aureus, beta-haemolytic streptococci, Streptococcus pneumoniae, Escherichia coli and Proteus mirabilis. Drug-related side-effects were reported in 7.2% of the patients.
头孢羟氨苄是一种新型半合成口服头孢菌素，空腹和非空腹受试者对其吸收情况相似，能产生持续的血清浓度，且消除速率相对较慢。这些药代动力学特性使得其给药方案比头孢氨苄和头孢拉定更不频繁、更方便，从而提高了患者的依从性。对1051例患者进行了头孢羟氨苄的安全性评估，对1030例患者进行了疗效评估。总体而言，881例完全治愈和65例临床治愈，临床成功率达到91.8%。在363例呼吸道感染患者和471例泌尿生殖道感染患者中，头孢羟氨苄治疗的临床成功率分别为97.5%和84.5%。在其余接受治疗的传染病中，头孢羟氨苄治疗的临床成功率为99.0%。头孢羟氨苄清除了分离出的1110种病原体中的87%，其中最主要的病原体是金黄色葡萄球菌、β溶血性链球菌、肺炎链球菌、大肠杆菌和奇异变形杆菌。7.2%的患者报告了与药物相关的副作用。
